Recent Updates
Recently added Catalysts
OVID Neutral Sentiment

RDCC

Friday, September 29, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ovid Therapeutics provides an overview of its company structure, pipeline programs, and culture. The article highlights various aspects such as leadership, scientific strategy, and investor relations. It also mentions ongoing collaborations and the company's commitment to its patients. However, no specific news or developments are detailed.
Price reaction · baseline $3.77 (2023-09-28 close) · hit pre-market · 2 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+1.9%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

• Our Company Our Story Leadership Board of Directors Scientific Advisory Board
• Our Science Our Pipeline Programs OV329 OV4071 & KCC2 Portfolio Program Posters and Publications Our Scientific Strategy Our Collaborations
• Our Patients
• Our Culture & Careers Our Culture Life at Ovid Our Values Open Positions
• Investors News Events & Presentations Stock Information Financials Governance Publications and Posters
• Contact Us
• Program Posters and Publications
• Our Story
• Leadership
• Board of Directors
• Scientific Advisory Board
• Our Pipeline
• Programs OV329 OV4071 & KCC2 Portfolio
• Program Posters and Publications
• Our Scientific Strategy
• Our Collaborations
• OV329
• OV4071 & KCC2 Portfolio
• Our Culture
• Life at Ovid
• Our Values
• Open Positions
• News
• Events & Presentations
• Stock Information
• Financials
• Governance
• Publications and Posters
ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid Therapeutics pipeline programs leadership investor relations OV329
Last updated: Sep 29, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →